PT4122923T - Derivado de oxadiazole - Google Patents

Derivado de oxadiazole

Info

Publication number
PT4122923T
PT4122923T PT217708627T PT21770862T PT4122923T PT 4122923 T PT4122923 T PT 4122923T PT 217708627 T PT217708627 T PT 217708627T PT 21770862 T PT21770862 T PT 21770862T PT 4122923 T PT4122923 T PT 4122923T
Authority
PT
Portugal
Prior art keywords
oxadiazole derivative
oxadiazole
derivative
Prior art date
Application number
PT217708627T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of PT4122923T publication Critical patent/PT4122923T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT217708627T 2020-03-17 2021-03-16 Derivado de oxadiazole PT4122923T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020046138 2020-03-17

Publications (1)

Publication Number Publication Date
PT4122923T true PT4122923T (pt) 2025-12-03

Family

ID=77768228

Family Applications (1)

Application Number Title Priority Date Filing Date
PT217708627T PT4122923T (pt) 2020-03-17 2021-03-16 Derivado de oxadiazole

Country Status (16)

Country Link
US (2) US20230265061A1 (https=)
EP (1) EP4122923B1 (https=)
JP (2) JP7637121B2 (https=)
KR (1) KR20220154208A (https=)
CN (1) CN115515943B (https=)
AU (1) AU2021239631A1 (https=)
BR (1) BR112022017530A2 (https=)
CA (1) CA3170273A1 (https=)
DK (1) DK4122923T3 (https=)
ES (1) ES3041051T3 (https=)
FI (1) FI4122923T3 (https=)
MX (1) MX2022011483A (https=)
PH (1) PH12022552373A1 (https=)
PT (1) PT4122923T (https=)
TW (1) TWI879917B (https=)
WO (1) WO2021187486A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021187486A1 (ja) * 2020-03-17 2021-09-23 大日本住友製薬株式会社 オキサジアゾール誘導体
JP7653399B2 (ja) 2021-09-22 2025-03-28 住友ファーマ株式会社 オキサジアゾール誘導体を含有する医薬組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1227978A (https=) * 1968-09-13 1971-04-15
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
RU2426731C2 (ru) * 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
EP2109364A4 (en) * 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
GB0723814D0 (en) * 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
RU2010142655A (ru) * 2008-03-19 2012-04-27 Ауриммед Фарма, Инк. (Us) Соединение, пригодное для лечения болезней и нарушений центральной нервной системы, и способ его получения
US8691824B2 (en) * 2008-08-04 2014-04-08 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JPWO2010055911A1 (ja) * 2008-11-14 2012-04-12 大日本住友製薬株式会社 ビフェニルアセトアミド誘導体
WO2011145669A1 (ja) * 2010-05-19 2011-11-24 大日本住友製薬株式会社 アミド誘導体
JP2012001537A (ja) * 2010-05-19 2012-01-05 Dainippon Sumitomo Pharma Co Ltd ビフェニルアセトアミド誘導体からなる医薬
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
WO2013062027A1 (ja) * 2011-10-27 2013-05-02 大正製薬株式会社 アゾール誘導体
JP2013221025A (ja) * 2012-04-19 2013-10-28 Dainippon Sumitomo Pharma Co Ltd ビフェニルアセトアミド誘導体の製造方法及びその中間体
US20150299178A1 (en) * 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
JP6387669B2 (ja) * 2013-04-26 2018-09-12 大正製薬株式会社 アゾール誘導体を含有する医薬
WO2015161014A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
WO2017066103A1 (en) * 2015-10-16 2017-04-20 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
JP2018531975A (ja) * 2015-10-30 2018-11-01 ピーティーシー セラピューティクス,インコーポレーテッド てんかんの治療方法
WO2021187486A1 (ja) * 2020-03-17 2021-09-23 大日本住友製薬株式会社 オキサジアゾール誘導体

Also Published As

Publication number Publication date
KR20220154208A (ko) 2022-11-21
TW202146392A (zh) 2021-12-16
US20230265061A1 (en) 2023-08-24
US11718592B2 (en) 2023-08-08
AU2021239631A8 (en) 2022-12-01
JPWO2021187486A1 (https=) 2021-09-23
AU2021239631A1 (en) 2022-11-10
JP7637121B2 (ja) 2025-02-27
ES3041051T3 (en) 2025-11-06
TWI879917B (zh) 2025-04-11
DK4122923T3 (da) 2025-12-15
FI4122923T3 (fi) 2025-11-12
CN115515943B (zh) 2024-07-09
PH12022552373A1 (en) 2023-12-18
MX2022011483A (es) 2022-10-07
EP4122923A1 (en) 2023-01-25
JP2025081449A (ja) 2025-05-27
CA3170273A1 (en) 2021-09-23
WO2021187486A1 (ja) 2021-09-23
EP4122923B1 (en) 2025-09-10
CN115515943A (zh) 2022-12-23
BR112022017530A2 (pt) 2022-10-18
EP4122923A4 (en) 2024-04-24
US20230092498A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
EP4253377A4 (en) 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE
DK4067344T3 (da) Cycloalkylurinstofderivat
EP4186256C0 (en) INTER-AGENCY COMMUNICATION VIA AN AD-HOC NETWORK SLICE
EP4137404A4 (en) Multicopter
EP4107782A4 (en) MICROARRAYS
EP4301748C0 (en) TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
EP3957265A4 (en) MICROSCOPE COVER
EP3885347A4 (en) DIHYDROPYRROLOPYRAZOLE DERIVATIVE
IL304774A (en) Enhanced sophorolipid derivatives
DK4396183T3 (da) Substituerede s-alaninatderivater
EP4308572C0 (en) NEW THIENOPYRIMIDINONE DERIVATIVES
EP4063561C0 (en) REFINER SEGMENT
EP4163277C0 (en) NEW PYRAZOLE DERIVATIVES
EP4121679C0 (de) Mehrschlauchanordnung
PT4122923T (pt) Derivado de oxadiazole
EP4357336A4 (en) BENZOXAZINONE DERIVATIVES
EP3770162A4 (en) DIHYDROCHROME DERIVATIVE
EP4308576C0 (en) NEW THIAZOLOPYRIMIDINONE DERIVATIVES
EP4166541A4 (en) Dimethylsulfoximine derivative
EP4154884A4 (en) Anti-sars-cov-2 durg
EP4137402A4 (en) MULTICOPTER
EP3741757A4 (en) DIHYDROINDOLIZINONE DERIVATIVE
EP4361159A4 (en) Borono-phenylalanine derivative
EP4140985A4 (en) 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE
EP4320989A4 (en) MR-DC IMPROVEMENTS